Save Product
Product Details
Synonym
CD258 antigen, CD258, HVEM-L, LIGHT, LTg, TNFSF14, TR2, HVEML
Source
Human LIGHT Protein, His Tag (LIT-H5243) is expressed from human 293 cells (HEK293). It contains AA Asp 74 - Val 240 (Accession # O43557-1).
Predicted N-terminus: His
Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 58.3 kDa. The protein migrates as 50-60 kDa and 65-100 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.0005 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human LIGHT Protein, His Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Human LIGHT Protein, His Tag (Cat. No. LIT-H5243) is more than 90% and the molecular weight of this protein is around 60-80 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human LIGHT Protein, His Tag (Cat. No. LIT-H5243) at 5 μg/mL (100 μL/well) can bind Human LTBR, Fc Tag (Cat. No. LTR-H5259) with a linear range of 0.06-1 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Tumor necrosis factor superfamily member 14
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
2 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
Drug Candidate Licensing
